Back to Journals » Cancer Management and Research » Volume 10

Upregulated expression of miR-421 is associated with poor prognosis in non-small-cell lung cancer

Authors Li Y, Cui X, Li Y, Zhang T, Li S

Received 6 March 2018

Accepted for publication 22 May 2018

Published 13 August 2018 Volume 2018:10 Pages 2627—2633

DOI https://doi.org/10.2147/CMAR.S167432

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo


Yunxia Li,1 Xiaomei Cui,2 Yongdeng Li,3 Tingting Zhang,4 Shuyun Li5

1Department of Clinical Laboratory, Shouguang People’s Hospital, Shandong 262700, China; 2Department of Neurosurgery, Shouguang People’s Hospital, Shandong 262700, China; 3Department of Joint Surgery, Shouguang People’s Hospital, Shandong 262700, China; 4Hemodialysis Room, Shouguang People’s Hospital, Shandong 262700, China; 5Coronary Care Unit, Shouguang People’s Hospital, Shandong 262700, China

Background: Non-small-cell lung cancer (NSCLC) represents the most frequent subtype of lung cancer. MicroRNAs (miRNAs) have attracted a lot of attention with regard to their clinical significance and crucial biological functions in various human cancers. This study aimed to investigate the prognostic significance of microRNA-421 (miR-421) and its correlation with tumor progression in NSCLC.
Materials and methods: Expression levels of miR-421 in both serum and tissue samples were measured by quantitative real-time polymerase chain reaction (qRT-PCR). The prognostic value of miR-421 was evaluated using Kaplan–Meier survival analysis and Cox regression assay. To explore the functional role of miR-421 during NSCLC progression, cell experiments were carried out.
Results: Expression of serum and tissue miR-421 was upregulated in the NSCLC patients compared with the normal controls (all P<0.001), and the expression showed a significant correlation between the serum samples and tissues (R=0.475, P<0.001). The increased miR-421 expression was associated with positive lymph-node metastasis and advanced TNM stage (all P<0.05). Moreover, patients with high miR-421 expression had poor overall survival compared with those with low expression (log-rank P=0.007). The overexpression of miR-421 proved to be an independent prognostic factor for NSCLC (HR=1.991, 95% CI=1.046–3.791, P=0.036). According to the cell experiments, the proliferation, migration and invasion of NSCLC cells were suppressed by knockdown of miR-421.
Conclusion: Overexpression of miR-421 serves as a prognostic biomarker and may be involved in the promotion of tumor progression in NSCLC.

Keywords: miR-421, prognosis, progression, non-small-cell lung cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]